DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.

Revenue
+11.2%
EPS
0.00%
Free cash flow
−52.9%
Total debt
+0.31%

Quarter to September 2026, against a year earlier

79.50 4.96 −5.87%
Market cap
$31.5B
P/E
32.6×
Fwd P/E
31.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

34.50% 35.62% 38.49% 37.67%
Piotroski F-Score
8 9 8 8
ROA
13.04% 13.90% 14.51% 14.43%
ROIC
28.66% 36.21% 37.13% 39.00%
Return on Tangible Assets
24.24% 25.37% 30.24% 30.91%
Average Days of Receivables
95.21 82.47 92.38 84.82
Free Cash Flow per Share
2.76 3.71 3.68 2.93
Free Cash Flow
1,077.20 1,429.40 1,405.00 1,098.30
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026